This early-stage study tests a personalized vaccine (PGV001) combined with an immune booster (CDX-301) in 27 men who have had aggressive prostate cancer but currently show no signs of tumor. The goal is to see if the vaccine is safe and can train the immune system to recognize an…
Phase: PHASE1 • Sponsor: Ashutosh Kumar Tewari • Aim: ⭐️ VACCINE ⭐️
Last updated Jun 27, 2026 08:09 UTC